Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
Oncology（2023）
摘要
Safety and efficacy of SB3 demonstrated in this real-world study were comparable with previous studies of reference trastuzumab.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要